Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker BOLD
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Aug 27, 2026 | SCHEDULE 13G | BOLD Boundless Bio, Inc. | Zachary Hornby | 2.43M | 9.8% | SCHEDULE 13G ↗ |
| Aug 14, 2026 | SCHEDULE 13G | BOLD Boundless Bio, Inc. | Daniel Schneeberger | 1.97M | 8.8% | SCHEDULE 13G ↗ |
| Aug 14, 2026 | SCHEDULE 13G | BOLD Boundless Bio, Inc. | ADAR1 Capital Management, LLC | 1.97M | 8.8% | SCHEDULE 13G ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | BOLD Boundless Bio, Inc. | Kenneth Griffin | 145,118 | 0.6% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | BOLD Boundless Bio, Inc. | Citadel Securities GP LLC | 145,118 | 0.6% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | BOLD Boundless Bio, Inc. | Citadel Securities Group LP | 145,118 | 0.6% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | BOLD Boundless Bio, Inc. | Citadel Securities LLC | 65,617 | 0.3% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | BOLD Boundless Bio, Inc. | Citadel GP LLC | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | BOLD Boundless Bio, Inc. | Citadel Advisors Holdings LP | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | BOLD Boundless Bio, Inc. | Citadel Advisors LLC | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Jun 29, 2026 | SCHEDULE 13G | BOLD Boundless Bio, Inc. | Tang Capital Partners IV, Inc | 580,669 | 2.6% | SCHEDULE 13G ↗ |
| Jun 29, 2026 | SCHEDULE 13G | BOLD Boundless Bio, Inc. | Tang Capital Partners III, Inc | 580,668 | 2.6% | SCHEDULE 13G ↗ |
| Jun 29, 2026 | SCHEDULE 13G | BOLD Boundless Bio, Inc. | Tang Capital Partners International, LP | 791,839 | 3.5% | SCHEDULE 13G ↗ |
| Jun 29, 2026 | SCHEDULE 13G | BOLD Boundless Bio, Inc. | Tang Capital Partners, LP | 580,669 | 2.6% | SCHEDULE 13G ↗ |
| Jun 29, 2026 | SCHEDULE 13G | BOLD Boundless Bio, Inc. | Kevin Tang | 2.53M | 11.3% | SCHEDULE 13G ↗ |
| Jun 29, 2026 | SCHEDULE 13G | BOLD Boundless Bio, Inc. | Tang Capital Management, LLC | 2.53M | 11.3% | SCHEDULE 13G ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | BOLD Boundless Bio, Inc. | Rocco Sgobbo | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | BOLD Boundless Bio, Inc. | Costas Constantinides | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | BOLD Boundless Bio, Inc. | Ian Charoub | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | BOLD Boundless Bio, Inc. | Nextech VI Oncology SCSp | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | BOLD Boundless Bio, Inc. | Nextech VI GP S.a. r.l. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 5, 2026 | SCHEDULE 13G/A (amended) | BOLD Boundless Bio, Inc. | Abigail P. Johnson | 2.68M | 12.0% | SCHEDULE 13G/A ↗ |
| Feb 5, 2026 | SCHEDULE 13G/A (amended) | BOLD Boundless Bio, Inc. | FMR LLC | 2.68M | 12.0% | SCHEDULE 13G/A ↗ |
| Dec 4, 2025 | SCHEDULE 13G | BOLD Boundless Bio, Inc. | Kenneth Griffin | 1.43M | 6.4% | SCHEDULE 13G ↗ |
| Dec 4, 2025 | SCHEDULE 13G | BOLD Boundless Bio, Inc. | Citadel Securities GP LLC | 602,452 | 2.7% | SCHEDULE 13G ↗ |
| Dec 4, 2025 | SCHEDULE 13G | BOLD Boundless Bio, Inc. | Citadel Securities Group LP | 602,452 | 2.7% | SCHEDULE 13G ↗ |
| Dec 4, 2025 | SCHEDULE 13G | BOLD Boundless Bio, Inc. | Citadel Securities LLC | 602,452 | 2.7% | SCHEDULE 13G ↗ |
| Dec 4, 2025 | SCHEDULE 13G | BOLD Boundless Bio, Inc. | Citadel GP LLC | 830,936 | 3.7% | SCHEDULE 13G ↗ |
| Dec 4, 2025 | SCHEDULE 13G | BOLD Boundless Bio, Inc. | Citadel Advisors Holdings LP | 830,936 | 3.7% | SCHEDULE 13G ↗ |
| Dec 4, 2025 | SCHEDULE 13G | BOLD Boundless Bio, Inc. | Citadel Advisors LLC | 830,936 | 3.7% | SCHEDULE 13G ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | BOLD Boundless Bio, Inc. | RA Capital Healthcare Fund, L.P. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | BOLD Boundless Bio, Inc. | Rajeev Shah | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | BOLD Boundless Bio, Inc. | Peter Kolchinsky | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | BOLD Boundless Bio, Inc. | RA Capital Management, L.P. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
34 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 6:16 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances